These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35227940)

  • 1. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
    Rascol O; Tönges L; deVries T; Jaros M; Quartel A; Jacobs D;
    Parkinsonism Relat Disord; 2022 Mar; 96():65-73. PubMed ID: 35227940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amantadine Extended-Release (GOCOVRI
    Paik J; Keam SJ
    CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
    Pahwa R; Tanner CM; Hauser RA; Isaacson SH; Nausieda PA; Truong DD; Agarwal P; Hull KL; Lyons KE; Johnson R; Stempien MJ
    JAMA Neurol; 2017 Aug; 74(8):941-949. PubMed ID: 28604926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
    Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
    Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
    Hauser RA; Pahwa R; Tanner CM; Oertel W; Isaacson SH; Johnson R; Felt L; Stempien MJ
    J Parkinsons Dis; 2017; 7(3):511-522. PubMed ID: 28777755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
    Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J
    J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
    Elmer LW; Juncos JL; Singer C; Truong DD; Criswell SR; Parashos S; Felt L; Johnson R; Patni R
    CNS Drugs; 2018 Apr; 32(4):387-398. PubMed ID: 29532440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
    LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S
    Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
    Pajo AT; Espiritu AI; Jamora RDG
    Neurodegener Dis Manag; 2019 Aug; 9(4):205-215. PubMed ID: 31392922
    [No Abstract]   [Full Text] [Related]  

  • 12. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
    Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
    Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
    Elkurd MT; Bahroo LB; Pahwa R
    Neurodegener Dis Manag; 2018 Apr; 8(2):73-80. PubMed ID: 29564954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.
    Hauser RA; Goud S; Formella AE
    Clin Park Relat Disord; 2022; 6():100123. PubMed ID: 35059622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.
    Mehta SH; Pahwa R; Tanner CM; Hauser RA; Johnson R
    Neurol Ther; 2021 Jun; 10(1):307-320. PubMed ID: 33864229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
    Hauser RA; Kremens DE; Elmer LW; Kreitzman DL; Walsh RR; Johnson R; Howard R; Nguyen JT; Patni R
    J Parkinsons Dis; 2019; 9(3):591-600. PubMed ID: 31081793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
    Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
    Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W
    Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.